We here report on the implementation and clinical success of our epichaperome-directed diagnostic assay in a patient with refractory AML, which tumor harbored a novel PML-SYK fusion and epichaperome-driven aberrant PPI networks. The gene discussed is PML; the disease is neoplasm.